Literature DB >> 33993352

Lifetime evolution of ADHD treatment.

Federico Mucci1, Barbara Carpita2, Giovanni Pagni3, Alessandra Della Vecchia3, Sarah Bjedov4, Andrea Pozza5, Donatella Marazziti3,6.   

Abstract

Attention-deficit hyperactivity disorder (ADHD), has been traditionally considered a neurodevelopmental disorder affecting children and adolescents characterized by inattention, hyperactivity, disruptive behavior, and impulsivity. Although still debated, it is evident that ADHD is also present in adulthood, but this diagnosis is rarely carried out, mainly for the frequent comorbidity with other psychiatric and/or substance abuse disorders. Given the need to shed more light on the pharmacological treatment of ADHD, we performed a naturalistic review to review and comment on the available literature of ADHD treatment across the lifespan. Indeed, stimulants are endowed of a prompt efficacy and safety, whilst non-stimulants, although requiring some weeks to be fully effective, are useful when a substance abuse history is detected. In any case, the pharmacological management of ADHD appears to be still largely influenced by the individual experience of the clinicians. Further longitudinal studies with a careful and detailed characterization of participants across different phases of the lifespan are also required to provide relevant confirmations (or denials) regarding pharmacological treatments amongst the different age groups.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  ADHD; Lifespan management; Non-stimulants; Pharmacological treatment; Stimulants

Mesh:

Substances:

Year:  2021        PMID: 33993352     DOI: 10.1007/s00702-021-02336-w

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.850


  128 in total

1.  Pilot Study of Droxidopa With Carbidopa in Adults With ADHD.

Authors:  Lenard A Adler; Stephen W Gorny
Journal:  J Atten Disord       Date:  2015-04-23       Impact factor: 3.256

2.  Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder.

Authors:  Shahrokh Amiri; Sara Farhang; Mohammad Ali Ghoreishizadeh; Ayyoub Malek; Soleiman Mohammadzadeh
Journal:  Hum Psychopharmacol       Date:  2012-01-18       Impact factor: 1.672

Review 3.  Symptoms of fatigue and sleepiness in major depressive disorder.

Authors:  David S Baldwin; George I Papakostas
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

4.  Open-label trial of venlafaxine in adults with attention deficit disorder.

Authors:  L A Adler; S Resnick; M Kunz; O Devinsky
Journal:  Psychopharmacol Bull       Date:  1995

Review 5.  Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review.

Authors:  Kara Simone Bagot; Yifrah Kaminer
Journal:  Addiction       Date:  2014-04       Impact factor: 6.526

6.  Noradrenergic α2A-receptor stimulation in the ventral hippocampus reduces impulsive decision-making.

Authors:  Andrew R Abela; Yogita Chudasama
Journal:  Psychopharmacology (Berl)       Date:  2013-09-06       Impact factor: 4.530

Review 7.  Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).

Authors:  Cecilio Alamo; Francisco López-Muñoz; Javier Sánchez-García
Journal:  Actas Esp Psiquiatr       Date:  2016-05-01       Impact factor: 1.196

Review 8.  Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.

Authors:  Amy F T Arnsten; Lu E Jin
Journal:  Yale J Biol Med       Date:  2012-03-29

Review 9.  Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review.

Authors:  L Eugene Arnold; Paul Hodgkins; Hervé Caci; Jennifer Kahle; Susan Young
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

Review 10.  Differential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults.

Authors:  Philip Asherson; Allan H Young; Dominique Eich-Höchli; Paul Moran; Vibeke Porsdal; Walter Deberdt
Journal:  Curr Med Res Opin       Date:  2014-05-07       Impact factor: 2.580

View more
  1 in total

1.  Modulation of Spatial Memory Deficit and Hyperactivity in Dopamine Transporter Knockout Rats via α2A-Adrenoceptors.

Authors:  Natalia Kurzina; Anastasia Belskaya; Arina Gromova; Alla Ignashchenkova; Raul R Gainetdinov; Anna Volnova
Journal:  Front Psychiatry       Date:  2022-03-25       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.